TY  - JOUR
AU  - Stojsic, Jelena
AU  - Stankovic, Tijana
AU  - Stojković Burić, Sonja
AU  - Milinkovic, Vedrana
AU  - Dinić, Jelena
AU  - Milosevic, Zorica
AU  - Milovanovic, Zorka
AU  - Tanić, Nikola
AU  - Banković, Jasna Z.
PY  - 2015
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2005
AB  - Lung cancer is the most common cause of neoplasia-related death
   worldwide. Accounting for approximately 80\% of all lung carcinomas, the
   non-small cell lung carcinoma (NSCLC) is the most common clinical form
   with its two predominant histological types, adenocarcinoma (ADC) and
   squamous cell carcinoma (SCC). Although surgical resection is the most
   favorable treatment for patients with NSCLC, relapse is still high, so
   neoadjuvant chemotherapy (NAC) is an accepted treatment modality. In
   this study we examined whether some of the key molecules associated with
   the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways could have
   predictive and prognostic value for the NAC application. To that end we
   examined the expression status of PTEN, pAKT, pERK and loss of
   heterozygosity (LOH) of PTEN in two groups of NSCLC patients, those who
   received and those who did not receive NAG LOH PTEN and low pERK
   expression is shown to be correlated with the longest survival of
   patients with SCC and ADC, respectively, who received NAC. These results
   point that the application of NAC is beneficial in the NSCLC patients
   with specific molecular alterations which could further help to improve
   constant search for the druggable molecular targets used in personalized
   therapy. (C) 2014 Elsevier Inc. All rights reserved.
T2  - Experimental and Molecular Pathology
T1  - Prolonged survival after neoadjuvant chemotherapy related with specific
 molecular alterations in the patients with nonsmall-cell lung carcinoma
IS  - 1
VL  - 98
DO  - 10.1016/j.yexmp.2014.11.010
SP  - 27
EP  - 32
ER  - 

@article{
author = "Stojsic, Jelena and Stankovic, Tijana and Stojković Burić, Sonja and Milinkovic, Vedrana and Dinić, Jelena and Milosevic, Zorica and Milovanovic, Zorka and Tanić, Nikola and Banković, Jasna Z.",
year = "2015",
abstract = "Lung cancer is the most common cause of neoplasia-related death
   worldwide. Accounting for approximately 80\% of all lung carcinomas, the
   non-small cell lung carcinoma (NSCLC) is the most common clinical form
   with its two predominant histological types, adenocarcinoma (ADC) and
   squamous cell carcinoma (SCC). Although surgical resection is the most
   favorable treatment for patients with NSCLC, relapse is still high, so
   neoadjuvant chemotherapy (NAC) is an accepted treatment modality. In
   this study we examined whether some of the key molecules associated with
   the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways could have
   predictive and prognostic value for the NAC application. To that end we
   examined the expression status of PTEN, pAKT, pERK and loss of
   heterozygosity (LOH) of PTEN in two groups of NSCLC patients, those who
   received and those who did not receive NAG LOH PTEN and low pERK
   expression is shown to be correlated with the longest survival of
   patients with SCC and ADC, respectively, who received NAC. These results
   point that the application of NAC is beneficial in the NSCLC patients
   with specific molecular alterations which could further help to improve
   constant search for the druggable molecular targets used in personalized
   therapy. (C) 2014 Elsevier Inc. All rights reserved.",
journal = "Experimental and Molecular Pathology",
title = "Prolonged survival after neoadjuvant chemotherapy related with specific
 molecular alterations in the patients with nonsmall-cell lung carcinoma",
number = "1",
volume = "98",
doi = "10.1016/j.yexmp.2014.11.010",
pages = "27-32"
}

Stojsic, J., Stankovic, T., Stojković Burić, S., Milinkovic, V., Dinić, J., Milosevic, Z., Milovanovic, Z., Tanić, N.,& Banković, J. Z.. (2015). Prolonged survival after neoadjuvant chemotherapy related with specific
 molecular alterations in the patients with nonsmall-cell lung carcinoma. in Experimental and Molecular Pathology, 98(1), 27-32.
https://doi.org/10.1016/j.yexmp.2014.11.010

Stojsic J, Stankovic T, Stojković Burić S, Milinkovic V, Dinić J, Milosevic Z, Milovanovic Z, Tanić N, Banković JZ. Prolonged survival after neoadjuvant chemotherapy related with specific
 molecular alterations in the patients with nonsmall-cell lung carcinoma. in Experimental and Molecular Pathology. 2015;98(1):27-32.
doi:10.1016/j.yexmp.2014.11.010 .

Stojsic, Jelena, Stankovic, Tijana, Stojković Burić, Sonja, Milinkovic, Vedrana, Dinić, Jelena, Milosevic, Zorica, Milovanovic, Zorka, Tanić, Nikola, Banković, Jasna Z., "Prolonged survival after neoadjuvant chemotherapy related with specific
 molecular alterations in the patients with nonsmall-cell lung carcinoma" in Experimental and Molecular Pathology, 98, no. 1 (2015):27-32,
https://doi.org/10.1016/j.yexmp.2014.11.010 . .

TY  - JOUR
AU  - Milosevic, Zorica
AU  - Pešić, Milica
AU  - Stankovic, Tijana
AU  - Dinić, Jelena
AU  - Milovanovic, Zorka
AU  - Stojsic, Jelena
AU  - Džodić, Radan R.
AU  - Tanić, Nikola
AU  - Banković, Jasna Z.
PY  - 2014
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2133
AB  - Anaplastic thyroid carcinoma (ATC) is a rare, but aggressive and
   chemoresistant tumor with dismal prognosis. Most ATCs harbor mutations
   that activate RAS/MAPK/ERK and PI3K/AKT/mTOR pathways. Therefore, we
   investigated and correlated the expression of phosphatase and tensin
   homolog, pERK, and pAKT proteins as well as mutations of BRAF, RAS, and
   p53 genes in samples of patients with ATC. Furthermore, we evaluated the
   potential of inhibition of these pathways on chemosensitization of ATC
   using 2 thyroid carcinoma cell lines (FRO and SW1736). Our results
   revealed a negative correlation between the activity of RAS-MAPK-ERK and
   PI3K-AKT-mTOR pathways in samples of patients. To be specific, the
   PI3K-AKT-mTOR pathway was suppressed in patients with activated NRAS or
   high pERK expression. In vitro results suggest that the inhibition of
   either RAS-MAPK-ERK or PI3K-AKT-mTOR components may confer sensitivity
   of thyroid cancer cells to classic chemotherapeutics. This may form a
   basis for the development of novel genetic-based therapeutic approach
   for this cancer type.
T2  - Translational Research
T1  - Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to
 chemosensitize anaplastic thyroid carcinoma
IS  - 5
VL  - 164
DO  - 10.1016/j.trsl.2014.06.005
SP  - 411
EP  - 423
ER  - 

@article{
author = "Milosevic, Zorica and Pešić, Milica and Stankovic, Tijana and Dinić, Jelena and Milovanovic, Zorka and Stojsic, Jelena and Džodić, Radan R. and Tanić, Nikola and Banković, Jasna Z.",
year = "2014",
abstract = "Anaplastic thyroid carcinoma (ATC) is a rare, but aggressive and
   chemoresistant tumor with dismal prognosis. Most ATCs harbor mutations
   that activate RAS/MAPK/ERK and PI3K/AKT/mTOR pathways. Therefore, we
   investigated and correlated the expression of phosphatase and tensin
   homolog, pERK, and pAKT proteins as well as mutations of BRAF, RAS, and
   p53 genes in samples of patients with ATC. Furthermore, we evaluated the
   potential of inhibition of these pathways on chemosensitization of ATC
   using 2 thyroid carcinoma cell lines (FRO and SW1736). Our results
   revealed a negative correlation between the activity of RAS-MAPK-ERK and
   PI3K-AKT-mTOR pathways in samples of patients. To be specific, the
   PI3K-AKT-mTOR pathway was suppressed in patients with activated NRAS or
   high pERK expression. In vitro results suggest that the inhibition of
   either RAS-MAPK-ERK or PI3K-AKT-mTOR components may confer sensitivity
   of thyroid cancer cells to classic chemotherapeutics. This may form a
   basis for the development of novel genetic-based therapeutic approach
   for this cancer type.",
journal = "Translational Research",
title = "Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to
 chemosensitize anaplastic thyroid carcinoma",
number = "5",
volume = "164",
doi = "10.1016/j.trsl.2014.06.005",
pages = "411-423"
}

Milosevic, Z., Pešić, M., Stankovic, T., Dinić, J., Milovanovic, Z., Stojsic, J., Džodić, R. R., Tanić, N.,& Banković, J. Z.. (2014). Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to
 chemosensitize anaplastic thyroid carcinoma. in Translational Research, 164(5), 411-423.
https://doi.org/10.1016/j.trsl.2014.06.005

Milosevic Z, Pešić M, Stankovic T, Dinić J, Milovanovic Z, Stojsic J, Džodić RR, Tanić N, Banković JZ. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to
 chemosensitize anaplastic thyroid carcinoma. in Translational Research. 2014;164(5):411-423.
doi:10.1016/j.trsl.2014.06.005 .

Milosevic, Zorica, Pešić, Milica, Stankovic, Tijana, Dinić, Jelena, Milovanovic, Zorka, Stojsic, Jelena, Džodić, Radan R., Tanić, Nikola, Banković, Jasna Z., "Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to
 chemosensitize anaplastic thyroid carcinoma" in Translational Research, 164, no. 5 (2014):411-423,
https://doi.org/10.1016/j.trsl.2014.06.005 . .